Q3 EPS Forecast for Gain Therapeutics Raised by Analyst

Key Points

• Roth Capital has raised its Q3 2025 earnings per share (EPS) estimate for Gain Therapeutics to ($0.16), improving from the prior estimate of ($0.18), with a price target of $6.00.
• Gain Therapeutics' last reported EPS was ($0.19), which was below the consensus estimate of ($0.17).
• HC Wainwright maintained a "buy" rating and set a target price of $8.00 for the stock, with a consensus target price of $7.80 across five analysts.

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - Investment analysts at Roth Capital increased their Q3 2025 earnings per share (EPS) estimates for Gain Therapeutics in a note issued to investors on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings per share of ($0.16) for the quarter, up from their prior estimate of ($0.18). Roth Capital currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics' Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.81) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Thursday, July 3rd. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Gain Therapeutics currently has a consensus rating of "Buy" and an average target price of $7.80.

Gain Therapeutics Trading Down 4.5%

Shares of GANX stock traded down $0.08 during mid-day trading on Friday, reaching $1.69. 207,484 shares of the stock traded hands, compared to its average volume of 278,180. The stock's fifty day simple moving average is $1.68 and its two-hundred day simple moving average is $1.90. Gain Therapeutics has a 1-year low of $0.95 and a 1-year high of $3.19. The company has a market cap of $60.76 million, a price-to-earnings ratio of -2.68 and a beta of 0.10. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).

Institutional Trading of Gain Therapeutics

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after buying an additional 8,251 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $65,000. Northern Trust Corp grew its stake in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares during the period. Kovitz Investment Group Partners LLC acquired a new stake in shares of Gain Therapeutics in the 1st quarter valued at about $91,000. Finally, Marshall Wace LLP grew its stake in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares during the period. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.